Talis Biomedical Corporation

OTCPK:TLIS Voorraadrapport

Marktkapitalisatie: US$3.1m

Talis Biomedical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Rob Kelley

Algemeen directeur

US$1.0m

Totale compensatie

Percentage CEO-salaris54.1%
Dienstverband CEO2.9yrs
Eigendom CEO0.04%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur2.9yrs

Recente managementupdates

Recent updates

We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Aug 16
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate

Talis Biomedical reports Q2 results

Aug 02

Talis Biomedical Aims For Manufacturing Turnaround

Mar 17

Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Feb 08
Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Nov 04
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

Jul 21
Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?

News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

May 18
News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat

Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 14
Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Analyse CEO-vergoeding

Hoe is Rob Kelley's beloning veranderd ten opzichte van Talis Biomedical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$51m

Mar 31 2024n/an/a

-US$57m

Dec 31 2023US$1mUS$551k

-US$62m

Sep 30 2023n/an/a

-US$75m

Jun 30 2023n/an/a

-US$86m

Mar 31 2023n/an/a

-US$98m

Dec 31 2022US$2mUS$525k

-US$113m

Sep 30 2022n/an/a

-US$115m

Jun 30 2022n/an/a

-US$127m

Mar 31 2022n/an/a

-US$165m

Dec 31 2021US$2mUS$322k

-US$192m

Sep 30 2021n/an/a

-US$208m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$144m

Dec 31 2020US$2mUS$89k

-US$91m

Compensatie versus markt: De totale vergoeding ($USD 1.02M ) Rob } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Rob is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Rob Kelley (52 yo)

2.9yrs

Tenure

US$1,019,331

Compensatie

Mr. Robert Kelley, also known as Rob, MBA, has been Chief Executive Officer and Director of Talis Biomedical Corporation since December 8, 2021 and served as its Chief Commercial Officer since September 20...

Bestuursleden

NaamPositieTenureCompensatieEigendom
Robert Kelley
CEO & Director2.9yrsUS$1.02m0.037%
$ 1.2k
Kimberly Popovits
Lead Independent Director2.9yrsUS$117.10k0.76%
$ 23.4k
Randal Scott
Independent Director8.8yrsUS$100.27k6.3%
$ 194.2k

2.9yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TLIS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.